Immunome (NASDAQ:IMNM) Given "Outperform" Rating at Wedbush

Immunome (NASDAQ:IMNM - Get Free Report)'s stock had its "outperform" rating reiterated by research analysts at Wedbush in a report issued on Monday,RTT News reports. They currently have a $33.00 target price on the stock. Wedbush's price objective suggests a potential upside of 228.69% from the stock's previous close.

IMNM has been the subject of several other reports. Stephens started coverage on Immunome in a report on Friday, November 8th. They issued an "overweight" rating and a $30.00 target price for the company. Piper Sandler dropped their price objective on Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome has a consensus rating of "Buy" and a consensus price target of $28.83.

Immunome Trading Down 5.3 %

Shares of IMNM stock traded down $0.56 during trading on Monday, hitting $10.04. The company's stock had a trading volume of 1,035,892 shares, compared to its average volume of 637,222. The company has a market cap of $626.67 million, a PE ratio of -1.24 and a beta of 1.90. The business has a fifty day moving average of $11.77 and a 200-day moving average of $12.99. Immunome has a 52 week low of $8.97 and a 52 week high of $30.96.

Insider Activity at Immunome

In other news, CTO Philip Tsai purchased 21,000 shares of the firm's stock in a transaction dated Thursday, November 21st. The shares were purchased at an average price of $9.43 per share, with a total value of $198,030.00. Following the completion of the acquisition, the chief technology officer now owns 21,000 shares in the company, valued at $198,030. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Robert Lechleider purchased 15,805 shares of the firm's stock in a transaction dated Thursday, November 21st. The stock was purchased at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the acquisition, the insider now owns 15,805 shares of the company's stock, valued at approximately $149,831.40. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 102,862 shares of company stock worth $978,045. Insiders own 8.60% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. FMR LLC increased its stake in Immunome by 0.3% in the third quarter. FMR LLC now owns 4,224,700 shares of the company's stock valued at $61,765,000 after acquiring an additional 13,757 shares during the last quarter. Janus Henderson Group PLC increased its stake in Immunome by 10.3% in the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company's stock valued at $50,971,000 after acquiring an additional 324,614 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Immunome by 228.5% during the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company's stock valued at $20,731,000 after buying an additional 1,191,774 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Immunome by 13.6% during the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company's stock valued at $17,657,000 after buying an additional 144,557 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock valued at $10,684,000 after buying an additional 237,497 shares during the last quarter. Institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.